Reference market
Open- Regular hours
- 09:30 AM – 04:00 PM EST
- Next holiday
- Nov 26, 2026 · Thanksgiving Day
Equity
Hims & Hers Health, Inc. (HIMS) perpetual futures
HIMS perpetual futures on 19 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade HIMSUSDT.
Hims & Hers Health operates a digital health platform connecting consumers with licensed professionals for virtual care and wellness products.
$19.42-3.5%NYSE open
Price chart
Interactive TradingView chart
TradingView symbol NYSE:HIMS
Loads TradingView's third-party widget (about 1 MB) on demand.
Auto: underlying reference priceOpen in TradingView
Trading data
Perpetual market activity
19/19 live markets
Trading data
Perpetual market activity
Venues
19
Live markets
19/19
24h volume
$13.5MCoverage: 15/19 marketsExchange-reported volume: $16.4M
Open interest
$3.6MCoverage: 14/19 markets
Best liquidity
$1.7M
Ourbit
Tightest spread
+9.8 bps
Hyperliquid HIP-3
Highest volume
$8.8M
Deepcoin
Settlement mix
USDT · 15/19
Perp/spot vol.
0.05x
Spot volume $264.5M
OI / float
+0.09%
Float $4.1B
Spot performance
1D-5.19%
5D-23.47%
1M-33.59%
6M-18.27%
YTD-39.24%
1Y-45.27%
Venue matrix
19 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Binance | Trade | HIMS/USDT | Trading | $19.43 | 0.0% APR 0.000% every 8h | +15.5 bps | $602.5K | $1.5M | $714.6K | USDT | - | |
 Hyperliquid HIP-3 | Trade | xyz:HIMS | Trading | $19.41 | +5.5% APR +0.00063% every 1h | +9.8 bps | - | $1M | $1.6M | USDC | 10x | |
 OKX | Trade | HIMS/USDT | Trading | $19.43 | 0.0% APR 0.000% every 8h | +15.5 bps | $23.2K | $378.8K | $285.3K | USDT | 20x | |
 XT.com | Trade | HIMS/USDT | Trading | $19.43 | +11.6% APR +0.011% every 8h | +15.5 bps | $1.8K | $364.6K | - | USDT | 20x | |
 Gate.io | Trade | HIMS/USDT | Trading | $19.41 | 0.0% APR 0.000% every 8h | +21.2 bps | $14.2K | $156.4K | $111K | USDT | 25x | |
 MEXC | Trade | HIMS/USDT | Trading | $19.42 | 0.0% APR 0.000% every 8h | +15.5 bps | $696.9K | $135.6K | $152.5K | USDT | 50x | |
 Bitunix | Trade | HIMS/USDT | Trading | $19.41 | +1.8% APR +0.00164% every 8h | +20.7 bps | $1.6M | $119.6K | $12K | USDT | 20x | |
 HTX | Trade | HIMS/USDT | Trading | $19.39 | 0.0% APR 0.000% every 8h | +177.3 bps | $460 | $60.6K | $6.5K | USDT | - | |
 Helix (Injective) | Trade | HIMS/USDC | Trading | $19.42 | -24.1% APR -0.00275% every 1h | - | no public depth feed | $54.2K | - | USDC | 6x | |
 Bybit | Trade | HIMS/USDT | Trading | $19.42 | 0.0% APR 0.000% every 8h | +20.7 bps | $21.6K | $50K | $373.4K | USDT | 25x | |
 BloFin | Trade | HIMS/USDT | Trading | $19.42 | +0.7% APR +0.00065% every 8h | +20.7 bps | $541.2K | $14.4K | $32.4K | USDT | 20x | |
 Aster | Trade | HIMSUSDT | Trading | $19.47 | 0.0% APR 0.000% every 8h | +77.6 bps | $90.8K | $6.9K | $52K | USDT | - | |
 Crypto.com Exchange | Trade | HIMS/USD | Trading | $19.43 | -21.7% APR -0.00248% every 1h | +25.9 bps | $4.9K | $6.5K | $2.9K | USD | 50x | |
 Vest | Trade | HIMS/USDC | Trading | $19.41 | +5.0% APR +0.00057% every 1h | +26.0 bps | $705.6K | - | - | USDC | 10x | |
 Deepcoin | Trade | HIMS/USDT | Trading | $19.43 | - | +10.4 bps | $708.7K | $8.8M | - | USDT | 25x | |
 BingX | Trade | HIMS-USDT | Trading | $19.43 | +5.5% APR +0.00500% every 8h | +15.5 bps | $721.9K | $756.4K | - | USDT | - | |
 LBank | Trade | HIMS/USDT | Trading | $19.42 | 0.0% APR 0.000% every 8h | +10.3 bps | $988.2K | $1.4M⚠ | $7.7K | USDT | 50x | |
 Ourbit | Trade | HIMS/USDT | Trading | $19.42 | 0.0% APR 0.000% every 8h | +10.4 bps | $1.7M | $782.1K⚠ | $113.5K | USDT | 50x | |
 KuCoin | Trade | HIMS/USDT | Trading | $19.41 | 0.0% APR 0.000% every 8h | +88.1 bps | $12.2K | $777.1K⚠ | $141.1K | USDT | 20x |
Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| HIMSonOndo GM | $19.37 | -0.24% | $1.3M | $20.9M | Ethereum · BNB Smart Chain (BEP20) · Solana |
| HIMSTokenized | $19.38 | -0.19% | $518k | – | Robinhood Chain |
| HIMSBbStocks | $19.37 | -0.26% | $296k | $625k | BNB Smart Chain (BEP20) |
| HIMSRobinhood | $19.37 | -0.26% | $170k | $1.8M | Robinhood Chain |
| HIMSxxStocks | $19.96 | +2.78% | $26k | $443k | Solana · Ethereum · Mantle · Arbitrum |
| Exchange | Pair | Price | 24h Vol. | Liquidity |
|---|---|---|---|---|
 uniswapDEX · robinhood | HIMS/SPY ↗ | $19.37 | $170k | $151k |
 communityV3DEX · ethereum | HIMSon/USDC ↗ | $19.53 | $80k | $755k |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 13 of 19 venues absorb $10k · Typical cost: +12.9 bps – +33.9 bps
Too thin: KuCoin, Crypto.com Exchange, XT.com
No fresh book data: HTX, Hyperliquid HIP-3, Helix (Injective)
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
HIMSTightest spread
HIMSHighest volume
HIMSFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
Earnings
2027-02-22
Revenue est. $903M · Updated 2h ago
No unusual perp activity right now.
Reference data
Market context
Reference data
Market context
New York Stock Exchange
Extended-hours reference
Bid19.31
Ask19.33
Volume3,073,411
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-0.89$3.2B+35%8
FY 2027-0.02$3.9B+24%9
FY 20280.19$4.4B+14%6
FY 20290.57$4.9B+11%3
FY 20300.61$4.7B-4%2
Q1 2027-0.09$895.7M+47%3
Source: FMP · Consensus
Company events
62027-02-22EarningsActual - / Estimate 0.02-
2026-11-09Earnings · After market closeActual -0.14 / Estimate 0.0563Miss
2026-08-10Earnings · After market closeActual -0.37 / Estimate -0.0498Miss
2026-05-11EarningsActual -0.4 / Estimate 0.0254Miss
2026-02-23EarningsActual 0.07 / Estimate 0.02Beat
2025-11-03EarningsActual 0.06 / Estimate 0.09Miss
Peer comparison
Similar listed perpsRevenue mix
Latest annualUNITED STATESGeographic$2.2B
Non USGeographic$134M
Analysts
Price targets in USD| Consensus rating | Hold |
|---|---|
| Average 12-month price target | $31.88 |
| 12-month target range (low – high) | $25 – $40 |
| Ratings in the provider's consensus | 20 |
Price targets as of 2026-11-13
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 2 | 1 | 12 | 0 | 0 |
| Oct 2026 | 2 | 1 | 12 | 0 | 1 |
| Sep 2026 | 2 | 1 | 13 | 0 | 1 |
| Aug 2026 | 2 | 1 | 12 | 0 | 1 |
| Jul 2026 | 2 | 1 | 12 | 0 | 1 |
| Jun 2026 | 3 | 1 | 12 | 0 | 1 |
| May 2026 | 3 | 1 | 12 | 0 | 1 |
| Apr 2026 | 3 | 1 | 12 | 0 | 1 |
| Mar 2026 | 3 | 1 | 12 | 1 | 1 |
| Feb 2026 | 2 | 2 | 10 | 1 | 1 |
| Jan 2026 | 1 | 2 | 10 | 1 | 2 |
| Dec 2025 | 1 | 3 | 8 | 1 | 2 |
Ownership
Institutional · 2026-Q3Free float94.2%211.9M shares
Shares outstanding224.9M shares
Institutional22.9%336 investors
Investor count change-251
Reference market activity
HIMS-PERPDay range (Nov 12)$19.47$20.46
52 week$13.74$40.99
Spot volume13.6M
Average volume-
Price performance
111D-5.2%
5D-23.5%
1M-33.6%
3M-31.4%
6M-18.3%
YTD-39.2%
1Y-45.3%
3Y+181.9%
5Y+141.5%
10Y+101.3%
MAX+101.3%
Insider activity
FY2026 Q4Acquisitions0 transactions0 shares
Dispositions3 transactions8,923 shares
Purchases0Ratio 0
Sales3
Insider transactions
25DateReporting persontransactionssharesPriceFilings
Form 3 initial statement for director Andrew D Huberman of Hims & Hers Health (HIMS), filed 2026-11-12, covering one holding report dated 2026-11-04: 0 shares of common stock at $0.00, with no transaction code and 0 shares owned after.
Hims & Hers Chief Legal Officer Boughton Soleil sold 3,462 shares of Class A Common Stock at $27.60 on October 28, 2026, leaving 293,886 shares owned.
Hims & Hers officer Soleil Boughton sold 3,461 Class A shares at $29.06 on 2026-10-14, leaving 297,348 shares held.
Hims & Hers officer Franklin Jonathan M filed a Form 3 initial statement of beneficial ownership dated 2026-10-09, reporting 0 shares of common stock. No purchases or sales are reported.
Hims & Hers CFO Okupe Oluyemi sold 2,000 Class A common shares at $29.70 on Oct 1, 2026, leaving 234,527 shares owned, per a Form 4 filed Oct 2, 2026.
Hims & Hers officer (Chief Legal Officer) Boughton Soleil sold 3,461 Class A common shares at $29.17 on 2026-09-30, leaving 300,809 shares held.
CFO Oluyemi Okupe exercised 14,000 options at $5.01 and sold 29,277 Class A shares at $29.95, leaving 236,527 shares.
Hims & Hers CFO Okupe Oluyemi sold 12,313 Class A common shares at $28.82 on Sept 17, 2026, leaving 251,804 shares owned.
Hims & Hers officer Boughton Soleil (Chief Legal Officer) sold 6,236 shares of Class A Common Stock on 2026-09-16 at $27.86, leaving 304,270 shares owned.
Hims & Hers Health COO Chi Michael sold 14,027 Class A common shares on 2026-09-15 at $28.39 each, leaving 456,660 shares owned. Form 4 filed 2026-09-17.
Hims & Hers CTO Mohamed Elshenawy sold 7,954 Class A common shares at $28.39 on Sept 15, 2026, leaving 185,556 shares owned.
Chief Legal Officer Soleil Boughton sold 3,458 Class A common shares of Hims & Hers Health at $28.33 each on September 2, 2026.
Director and CEO Andrew Dudum reported a gift of 463,289 Class A shares and a separate disposition of 977,566 shares via other transaction, totaling 1.44M shares disposed, with no cash value.
Deborah M. Autor, Chief Policy Officer of Hims & Hers Health, sold 16,773 Class A common shares at $27.85 each on August 18, 2026. After the sale, she held 48,961 shares.
Okupe Oluyemi exercised options for 4,938 Class A shares and sold the same 4,938 shares in one open-market transaction, reducing his holdings to 264,117 shares.
Chief Legal Officer Soleil Boughton sold 25,111 Class A common shares at $27.55 each on August 19, 2026, leaving 313,964 shares owned.
Hims & Hers officer Boughton Soleil converted 23,856 restricted stock units into 42,261 Class A shares, then had 21,500 shares withheld at $28.15 for taxes. She held 339,075 shares afterward.
Filings
79 · Latest SEC filings2026-11-123Initial insider ownership statement (Form 3)
Form 3 initial statement for director Andrew D Huberman of Hims & Hers Health (HIMS), filed 2026-11-12, covering one holding report dated 2026-11-04: 0 shares of common stock at $0.00, with no transaction code and 0 shares owned after.
2026-10-294Insider transaction report (Form 4)
Hims & Hers Chief Legal Officer Boughton Soleil sold 3,462 shares of Class A Common Stock at $27.60 on October 28, 2026, leaving 293,886 shares owned.
2026-10-154Insider transaction report (Form 4)
Hims & Hers officer Soleil Boughton sold 3,461 Class A shares at $29.06 on 2026-10-14, leaving 297,348 shares held.
2026-10-153Initial insider ownership statement (Form 3)
Hims & Hers officer Franklin Jonathan M filed a Form 3 initial statement of beneficial ownership dated 2026-10-09, reporting 0 shares of common stock. No purchases or sales are reported.
2026-10-024Insider transaction report (Form 4)
Hims & Hers CFO Okupe Oluyemi sold 2,000 Class A common shares at $29.70 on Oct 1, 2026, leaving 234,527 shares owned, per a Form 4 filed Oct 2, 2026.
2026-10-024Insider transaction report (Form 4)
Hims & Hers officer (Chief Legal Officer) Boughton Soleil sold 3,461 Class A common shares at $29.17 on 2026-09-30, leaving 300,809 shares held.
2026-09-234Insider transaction report (Form 4)
CFO Oluyemi Okupe exercised 14,000 options at $5.01 and sold 29,277 Class A shares at $29.95, leaving 236,527 shares.
2026-09-184Insider transaction report (Form 4)
Hims & Hers CFO Okupe Oluyemi sold 12,313 Class A common shares at $28.82 on Sept 17, 2026, leaving 251,804 shares owned.
2026-09-174Insider transaction report (Form 4)
Hims & Hers CTO Mohamed Elshenawy sold 7,954 Class A common shares at $28.39 on Sept 15, 2026, leaving 185,556 shares owned.
2026-09-174Insider transaction report (Form 4)
Hims & Hers officer Boughton Soleil (Chief Legal Officer) sold 6,236 shares of Class A Common Stock on 2026-09-16 at $27.86, leaving 304,270 shares owned.
2026-09-174Insider transaction report (Form 4)
Hims & Hers Health COO Chi Michael sold 14,027 Class A common shares on 2026-09-15 at $28.39 each, leaving 456,660 shares owned. Form 4 filed 2026-09-17.
2026-09-034Insider transaction report (Form 4)
Chief Legal Officer Soleil Boughton sold 3,458 Class A common shares of Hims & Hers Health at $28.33 each on September 2, 2026.
2026-08-274Insider transaction report (Form 4)
Director and CEO Andrew Dudum reported a gift of 463,289 Class A shares and a separate disposition of 977,566 shares via other transaction, totaling 1.44M shares disposed, with no cash value.
2026-08-204Insider transaction report (Form 4)
Deborah M. Autor, Chief Policy Officer of Hims & Hers Health, sold 16,773 Class A common shares at $27.85 each on August 18, 2026. After the sale, she held 48,961 shares.
2026-08-204Insider transaction report (Form 4)
Chief Legal Officer Soleil Boughton sold 25,111 Class A common shares at $27.55 each on August 19, 2026, leaving 313,964 shares owned.
2026-08-204Insider transaction report (Form 4)
Okupe Oluyemi exercised options for 4,938 Class A shares and sold the same 4,938 shares in one open-market transaction, reducing his holdings to 264,117 shares.
2026-08-184Insider transaction report (Form 4)
Hims & Hers officer Boughton Soleil converted 23,856 restricted stock units into 42,261 Class A shares, then had 21,500 shares withheld at $28.15 for taxes. She held 339,075 shares afterward.
2026-08-184Insider transaction report (Form 4)
On August 14, 2026, CTO Mohamed Elshenawy converted 188,285 RSUs into common stock and sold 95,798 shares at $28.15 for tax withholding.
2026-08-184Insider transaction report (Form 4)
David B. Wells, a director of Hims & Hers Health, converted 778 restricted stock units into 778 shares of Class A Common Stock on August 14, 2026, at no cost.
2026-08-184Insider transaction report (Form 4)
Hims & Hers officer Carroll Patrick Harrison converted 26,187 restricted stock units into 26,187 Class A shares, and 10,201 shares were disposed at $28.15 for tax withholding. No open-market purchases or sales.
2026-08-184Insider transaction report (Form 4)
Director Payne Christopher D converted 545 restricted stock units into 545 common shares of Hims & Hers Health (HIMS), at no cost, on 2026-08-14.
2026-08-184Insider transaction report (Form 4)
Irene Becklund, officer of Hims & Hers Health, converted 13,685 RSUs into common stock, and 6,490 shares were withheld for taxes.
2026-08-184Insider transaction report (Form 4)
Director Schultz Kare converted 6,623 restricted stock units into 6,623 Class A common shares on August 14, 2026.
2026-08-184Insider transaction report (Form 4)
HIMS COO Chi Michael exercised 86,265 restricted stock units into 86,265 Class A shares, then disposed of 47,702 shares at $28.15 to cover taxes.
2026-08-184Insider transaction report (Form 4)
CFO Okupe Oluyemi converted RSUs and options into 81,004 Class A shares, then sold 64,771 and had 36,437 withheld for taxes.
2026-08-184Insider transaction report (Form 4)
On 2026-08-14, Deborah M. Autor converted 32,920 restricted stock units into 32,920 Class A common shares; 16,147 shares were withheld to cover taxes at $28.15 each.
2026-08-184Insider transaction report (Form 4)
Hims & Hers CEO Andrew Dudum converted 154,993 RSUs into 154,993 Class A shares on 2026-08-14, then had 78,859 shares withheld at $28.15 for taxes, leaving 1,033,177 shares owned.
2026-08-144Insider transaction report (Form 4)
On August 12, 2026, Chief Medical Officer Patrick Harrison received a restricted stock unit award of 260 shares (valued at $0) from Hims & Hers Health, Inc.
2026-08-144Insider transaction report (Form 4)
Director Kofi Owusu received 21,380 restricted stock units in two awards on 2026-08-12, at no cost.
2026-08-144Insider transaction report (Form 4)
Director Kare Schultz received a grant of 8,223 restricted stock units (RSUs) on August 12, 2026.
2026-08-144Insider transaction report (Form 4)
Director David B. Wells received 9,001 restricted stock units in two awards from Hims & Hers Health, Inc. on August 12, 2026, at no cost.
2026-08-144Insider transaction report (Form 4)
Deborah M. Autor, Chief Policy Officer of Hims & Hers Health, received 8,223 restricted stock units as compensation; no cash was paid.
2026-08-144Insider transaction report (Form 4)
Director Cosgrove Delos M. received an award of 8,223 restricted stock units on 2026-08-12.
2026-08-144Insider transaction report (Form 4)
Director Andrea G Perez Garcia was awarded 8,223 restricted stock units (RSUs) on 2026-08-12, now holding 8,223 RSUs.
2026-08-144Insider transaction report (Form 4)
Director Manuel Anja received 8,223 restricted stock units as a compensation award on August 12, 2026, with no cash involved.
2026-08-144Insider transaction report (Form 4)
Director Payne Christopher D received 8,768 restricted stock units in 2 awards on 2026-08-12, at no cost.
2026-08-144Insider transaction report (Form 4)
CTO Mohamed Elshenawy was awarded 1,200,000 restricted stock units (RSUs) at $0.00, increasing his holdings to 1,200,000 shares.
2026-07-204Insider transaction report (Form 4)
HIMS CFO Oluyemi Okupe exercised stock options for 7,163 Class A shares at $5.01 each, then sold all 7,163 shares on the open market at $31.9933 each.
2026-07-074Insider transaction report (Form 4)
CFO Oluyemi Okupe exercised stock options for 7,163 Class A shares at $5.01 each, then sold all 7,163 shares on the open market at $36.4863 each.
2026-06-234Insider transaction report (Form 4)
CFO Oluyemi Okupe exercised stock options for 6,376 Class A shares at $5.01 each, then sold 18,197 Class A shares at an average price of $34.0285.
2026-06-234Insider transaction report (Form 4)
Hims & Hers CMO Patrick Harrison Carroll sold 23,726 shares of Class A Common Stock at $35 on 2026-06-18, leaving 181,861 shares owned afterward.
2026-06-174Insider transaction report (Form 4)
Hims & Hers officer Patrick Carroll converted 25,926 restricted stock units into 25,926 Class A shares, then 8,310 shares were withheld for tax at $30.17, leaving 205,587 shares owned.
2026-06-174Insider transaction report (Form 4)
Deborah Autor converted 32,919 RSUs into 32,919 Class A shares; 15,396 shares were then withheld for taxes at $30.17 each.
2026-06-174Insider transaction report (Form 4)
Hims & Hers CTO Mohamed Elshenawy converted 282,597 RSUs into 282,597 Class A shares. 151,534 shares were withheld for taxes at $30.17, and 30,040 shares were sold on the open market at $31.50.
2026-06-174Insider transaction report (Form 4)
CFO Oluyemi Okupe converted 71,616 RSUs into 71,616 Class A shares, then had 39,541 shares withheld to cover taxes at $30.17 each, leaving 296,142 shares owned.
2026-06-174Insider transaction report (Form 4)
HIMS COO Michael Chi converted 86,264 RSUs into 86,264 Class A shares, had 47,699 shares withheld for taxes at $30.17, and sold 14,027 shares at $31.50, leaving 432,124 shares owned.
2026-06-174Insider transaction report (Form 4)
Irene Becklund (PAO) converted 15,971 RSUs into 15,971 Class A shares; 5,870 shares were withheld for taxes at $30.17, and 12,063 shares were sold at $30.25-$31.50.
2026-06-174Insider transaction report (Form 4)
Chief Legal Officer Boughton Soleil converted 42,261 RSUs into 42,261 Class A shares; 23,315 shares were then withheld to cover taxes at $30.17 each.
2026-06-174Insider transaction report (Form 4)
CEO Andrew Dudum converted 154,991 RSUs into 154,991 Class A shares; 85,632 of those shares were withheld for taxes at $30.17.
2026-06-154Insider transaction report (Form 4)
Director Deborah M. Autor converted 3,656 restricted stock units into 3,656 Class A common shares of Hims & Hers Health, Inc., with no cash paid.
2026-06-153Initial insider ownership statement (Form 3)
A director of Hims & Hers Health filed a Form 3, reporting 0 shares acquired and 0 owned.
2026-06-154Insider transaction report (Form 4)
On June 11, 2026, director Andrea G Perez Garcia converted 3,656 RSUs into an equal number of Class A common shares at $0.00, holding 83,822 shares after.
2026-06-154Insider transaction report (Form 4)
Patrick Carroll, Chief Medical Officer of Hims & Hers Health, converted RSUs into 4,091 Class A common shares, with 435 RSUs disposed. No cash involved.
2026-06-154Insider transaction report (Form 4)
Director Christopher D. Payne reported conversion of 14,343 restricted stock units into 14,343 Class A common shares at $0.00 in three transactions on June 11 and 15, 2026, covering two RSU grants.
2026-06-154Insider transaction report (Form 4)
Director Pendarvis Christiane converted 3,656 restricted stock units into 3,656 Class A common shares on June 11, 2026.
2026-06-154Insider transaction report (Form 4)
On June 11 and 15, 2026, director Manuel Anja converted 13,696 restricted stock units into Class A common stock at $0.00 per share. Ownership rose to 38,671 shares.
2026-06-154Insider transaction report (Form 4)
Director Cosgrove Delos M. converted 3,656 restricted stock units into 3,656 Class A common shares on June 11, 2026.
2026-06-154Insider transaction report (Form 4)
Director David B. Wells converted 4,613 RSUs into Class A common stock on Jun 11 and 15, 2026, with 957 RSUs cancelled. No cash involved.
2026-06-154Insider transaction report (Form 4)
Director Schultz Kare converted 3,656 restricted stock units into 3,656 Class A common shares on June 11, 2026.
2026-05-264Insider transaction report (Form 4)
Director David B. Wells purchased 48,400 Class A common shares of Hims & Hers Health on May 26, 2026, at $24.235 each, increasing his holdings to 224,417 shares.
2026-05-224Insider transaction report (Form 4)
Patrick Carroll, Chief Medical Officer at Hims & Hers Health, received a restricted stock unit award of 435 shares on May 20, 2026.
2026-05-224Insider transaction report (Form 4)
Director Christopher D. Payne received a grant of 647 restricted stock units in Hims & Hers Health, Inc. on May 20, 2026.
2026-05-224Insider transaction report (Form 4)
David B. Wells, a director of Hims & Hers Health, Inc., received an award of 957 restricted stock units on May 20, 2026.
2026-05-194Insider transaction report (Form 4)
CFO Oluyemi Okupe exercised options for 7,950 Class A shares at $5.01 and sold them at $23.64 on May 18, 2026.
Transcripts
Earnings callsFY2026 Q12026-05-11
Earnings calls
AI summary
positiveHims & Hers achieved record-level weight loss subscriber additions following its March pivot to branded GLP-1 products, including Novo Nordisk's Wegovy, with over 125,000 Wegovy shipments fulfilled within 6 weeks. The company raised 2026 revenue guidance to $2.8B-$3B (19-28% growth) and adjusted EBITDA guidance to $275M-$350M despite $33M in restructuring charges related to the compounded GLP-1 supply chain write-down. International operations grew significantly with revenue increasing nearly 10x to $78M following ZAVA and Livewell acquisitions.
Key takeaways
- Strategic pivot to branded weight loss products driving over 100,000 new subscribers monthly with 90% app download rate and 3 provider interactions per user in first month
- Completed YourBio acquisition to enable at-home blood sampling for deeper health insights and preventative care expansion
- AI infrastructure advances include Labs AI agent for biomarker analysis, provider-side AI copilot, and upcoming AI weight loss companion with clinician verification embedded throughout
- Planned Eucalyptus acquisition ($240M upfront payment plus earn-outs through 2029) expected to close H2 2026, expanding market presence in Australia, UK, Germany, Japan and Canada
- Peptide category positioning with domestic supply chain, 503A compounding infrastructure and clinical protocols; awaiting July FDA guidance on reclassification
Financial highlights
- Q1 2026 revenue $608M (+4% YoY); subscribers 2.6M (+9% YoY); adjusted EBITDA $44M (7% margin)
- Q1 gross margin 65% GAAP, 70% adjusted (excluding $28M restructuring charges); international revenue $78M (nearly 10x growth)
- Operating cash flow $89M; free cash flow $53M; cash and short-term investments $751M
- FY2026 guidance: revenue $2.8B-$3B (19-28% growth); adjusted EBITDA $275M-$350M (11% margin midpoint); Q2 revenue $680M-$700M (25-28% growth)
Guidance
- 2026 full-year revenue $2.8B-$3B (19-28% YoY growth) and adjusted EBITDA $275M-$350M with 11% adjusted EBITDA margin midpoint
- Q2 2026 revenue $680M-$700M (25-28% growth) and adjusted EBITDA $35M-$55M (7% margin midpoint)
- Expect meaningful EBITDA step-up in Q3 and Q4 from monthly cohort compounding and continued G&A leverage
- 2030 targets: at least $6.5B revenue and $1.3B adjusted EBITDA; expect return to GAAP net income profitability in 2027
Q&A themes
- AI roadmap includes multi-agent model supporting entire customer journey from intake through ongoing care, with Labs AI and weight loss companion as first iterations; long-term vision to integrate throughout experience globally
- Peptide opportunity viewed as 'best in market not first to market' with focus on physician oversight, validated supply chains, clinical protocols and data transparency; competitive advantages from 1M+ sq ft 503A compounding footprint and domesticated API manufacturing facility
- Wearables strategy includes both proprietary hardware development (similar to YourBio) and integration partnerships with existing ecosystem players to provide universal data inputs
- New specialties (testosterone, menopause, labs) primarily U.S.-based for iteration with 6-9 month rollout to international geographies; international markets already operating branded pharmaceutical models for weight loss
Risks
- Strategic pivot to branded weight loss products incurred $33M restructuring charges and created near-term revenue recognition volatility from shift to 1-month shipment cadences; gross margins expected to compress several points in coming quarters
- Substantial investment required in technology, operations, and international expansion (Eucalyptus acquisition) may pressure near-term profitability; Eucalyptus timing uncertainty excluded from current guidance
- Peptides category development contingent on FDA reclassification guidance in July 2026; company taking intentionally measured approach rather than first-to-market, delaying revenue realization
FY2025 Q42026-02-23
Earnings calls
AI summary
positiveHims & Hers achieved strong 2025 results with $2.35B revenue (+59% YoY) and $318M adjusted EBITDA, reaching over 2.5M subscribers with 65% utilizing personalized treatments. The company is pursuing aggressive international expansion through acquisitions of ZAVA, Livewell, and Eucalyptus while launching new domestic offerings in labs, testosterone support, and menopause/perimenopause treatments. Management targets $6.5B revenue and $1.3B adjusted EBITDA by 2030.
Key takeaways
- 2025 revenue reached $2.35B (+59% YoY) with Q4 revenue of $618M (+28% YoY); adjusted EBITDA margin expanded to 14% for full year
- Subscriber base grew to 2.5M with 65% utilizing personalized treatments; monthly revenue per subscriber increased 11% YoY to $83
- Launched three new specialties in 2025 (Labs, testosterone support, menopause/perimenopause) with early signals suggesting each can reach $100M annual revenue
- Announced acquisition of Eucalyptus for up to $1.15B to expand into Australia, Japan, Germany, and deepen Western Europe presence; expects international business to break even within 12-18 months post-close
- 2026 guidance: $2.7B-$2.9B revenue (+15% to +24% YoY) and $300M-$375M adjusted EBITDA (12% margin at midpoint)
Financial highlights
- FY2025 revenue: $2.35B (+59% YoY); Q4 revenue: $618M (+28% YoY)
- FY2025 adjusted EBITDA: $318M (+80% YoY), 14% margin; Q4 adjusted EBITDA: $66M, 11% margin
- U.S. revenue grew over 50% YoY to $2.2B; international revenue grew 400% YoY to $134M
- FY2025 net income: $128M; operating cash flow: $300M; free cash flow: $57M; ended year with $929M cash and investments
Guidance
- Q1 2026: Revenue $600M-$625M (+2% to +7% YoY); adjusted EBITDA $35M-$55M (7% margin at midpoint)
- FY2026: Revenue $2.7B-$2.9B (+15% to +24% YoY); adjusted EBITDA $300M-$375M (12% margin at midpoint)
- International markets expected to contribute at least $200M in FY2026; Eucalyptus (if closed in H2) expected to add at least $200M additional second-half revenue
- Weight loss offering to face ~$65M Q1 revenue headwind from shift to 503(a) fulfillment timing; expect $1 billion+ first-year revenue for Hers brand in 2026
Q&A themes
- Regulatory scrutiny on compounded GLP-1s: Company positioned with diverse revenue streams (majority from non-GLP-1 offerings); weight loss business scaled to $100M run rate in 7 months pre-compounding; plan to continue expanding assortment with next-gen therapies
- Labs and wearables flywheel: 70% of Labs customers identified treatable conditions; company investing in YourBio for at-home blood testing; plans deeper integration of wearables and polygenic risk scores
- International expansion strategy: Plan to achieve Hims & Hers brand unification across major markets within 1-2 years; international business expected to mirror diversified U.S. specialty mix; strong relationships maintained with brand pharmaceutical companies
- Marketing efficiency improvements: 7-point YoY marketing leverage in 2025; Super Bowl commercial investment expected to drive payback in under one year; acquiring customers at lower cost through non-paid channels
Risks
- Regulatory and legal scrutiny on compounded GLP-1s and broader practices; company pulled compounded GLP-1 pill from market post-launch to prioritize ecosystem relationships
- Weight loss revenue timing headwinds from shift to 503(a) fulfillment (~$65M Q1 headwind); compounded GLP-1 revenue declining due to lower per-order values relative to core business
- International expansion dependent on successful integration of acquisitions (ZAVA, Livewell, Eucalyptus) and achieving profitability; majority of new international markets expected to run at breakeven initially
FY2025 Q32025-11-03
Earnings calls
AI summary
positiveQ3 revenue grew 49% YoY to nearly $600 million with adjusted EBITDA of $78 million (50% YoY growth). The company is expanding beyond treating existing conditions into proactive health management through comprehensive lab testing launching before year-end and a longevity specialty launching in 2026. Strategic partnerships with Novo Nordisk (Wegovy), Marius Pharmaceuticals (testosterone), and investment in GRAIL (cancer detection) position the platform for broader healthcare ecosystem integration.
Key takeaways
- Q3 revenue of $599 million (+49% YoY); adjusted EBITDA of $78 million (+50% YoY) with margins above 13%
- Subscribers using personalized solutions grew 50% YoY, driving nearly 50% revenue growth; total subscribers increased 20% YoY
- Launching comprehensive whole body lab testing before year-end and longevity specialty in 2026 featuring peptides, GLP-1s, and cardiometabolic treatments
- Strategic partnerships: Novo Nordisk (Wegovy injections and oral), Marius Pharmaceuticals (oral testosterone 2026), and GRAIL investment (multi-cancer early detection)
- Hers brand on pace for $1 billion revenue in 2026 with triple-digit growth; expanding into menopause, longevity, and diagnostics
Financial highlights
- Q3 2025 revenue: $599 million, +49% YoY; full-year guidance: $2.335-$2.355 billion (+58-59% YoY)
- Q3 adjusted EBITDA: $78 million (+50% YoY); full-year guidance: $307-$317 million with 13% margin at midpoint
- Q3 adjusted EBITDA margins above 13%; marketing as % of revenue 39% (6 points YoY leverage); gross margins 74%
- Q3 cash flow from operations: $149 million; free cash flow: $79 million; cash position: $1.1 billion total (including investments)
Guidance
- Q4 2025 revenue guidance: $605-$625 million (+26-30% YoY); adjusted EBITDA: $55-$65 million (10% margin at midpoint)
- Weight loss specialty on pace to achieve $725 million or greater for full year
- Q4 headwinds: $20-25 million from shorter GLP-1 shipment cadences; continued moderation in on-demand sexual health business
- 2030 targets: $6.5+ billion revenue and $1.3 billion adjusted EBITDA; expecting margin investments in 2026 before mid-term expansion
Q&A themes
- Diagnostics will accelerate new specialty launches and hyper-personalization; marketing will shift from stigmatized conditions toward wellness/longevity messaging to broader audiences
- GLP-1 portfolio strategy focuses on breadth of options (compounded, Novo Wegovy pill, next-gen therapies); price reductions driving demand expansion without long-term margin sacrifice through verticalization
- International expansion leveraging Zava acquisition; demand for high-touch, personalized care consistent globally; Canada launching soon with generic semaglutide partnerships; Brazil and Australia to follow
- Lab testing positioned as lead generation to personalized treatment offerings; company can undercut competitors on pricing due to core business focus on keeping customers healthy rather than testing margin optimization
Risks
- Q4 headwinds of $20-25 million from GLP-1 shipment cadence changes and continued moderation in on-demand sexual health business; near-term margin pressure expected from pricing reductions and new specialty investments
- Zava integration and international expansion require meaningful capital deployment and operational execution in unfamiliar regulatory/market environments; generic semaglutide competition launching 2026
- New specialties (menopause, longevity, diagnostics) and vertically integrated infrastructure represent unproven business models at scale; regulatory approval pending for Novo oral Wegovy and peptide access expansion dependent on current administration policy support
FY2025 Q22025-08-04
Earnings calls
AI summary
positiveHims & Hers delivered strong Q2 2025 results with revenue growth of 73% year-over-year to $545 million and adjusted EBITDA of $82 million (15%+ margin). The company is expanding its platform beyond weight loss into hormonal health, lab testing, and longevity services, with international expansion underway following the July acquisition of ZAVA. Full-year 2025 revenue guidance is $2.3-2.4 billion with adjusted EBITDA of $295-335 million.
Key takeaways
- Q2 revenue grew 73% YoY to $545M with 2.4M subscribers (+31% YoY, +73k QoQ) and adjusted EBITDA margins of 15%+
- Weight loss specialty achieved 10.3% average body weight loss over 6 months with only 25% discontinuation rate versus ~80% in comparable studies
- Upcoming launches include hormonal health (menopause and low testosterone), at-home lab testing as standalone service, and Canadian expansion in 2026 with generic semaglutide
- Completed ZAVA acquisition in July to establish platform in U.K., Germany, Ireland, and France with at least $50M net incremental revenue expected for remainder of 2025
- 2030 targets: at least $6.5B revenue and $1.3B adjusted EBITDA, with multiple $1B+ opportunity areas identified
Financial highlights
- Q2 2025 revenue: $545M (+73% YoY); adjusted EBITDA: $82M with 15%+ margin
- Subscribers: 2.4M (+31% YoY); monthly average revenue per subscriber: $74 (down from $84 QoQ due to GLP-1 offboarding)
- Full-year 2025 guidance: revenue $2.3-2.4B (+56-63% YoY); adjusted EBITDA $295-335M (13% margin at midpoint)
- Q3 2025 guidance: revenue $570-590M (+42-47% YoY); adjusted EBITDA $60-70M (11% margin at midpoint)
Guidance
- Full-year 2025 revenue: $2.3-2.4B; adjusted EBITDA: $295-335M (13% margin at midpoint)
- Weight loss specialty to deliver at least $725M revenue in 2025 across all components (oral, personalized semaglutide, liraglutide, branded)
- Q3 2025 revenue: $570-590M; adjusted EBITDA: $60-70M; expect positive free cash flow in second half 2025
- ZAVA acquisition to deliver at least $50M net incremental revenue for remainder of 2025; Canadian expansion planned for 2026
Q&A themes
- GLP-1 revenue dynamics: Q2 decrease from $230M to $190M primarily due to offboarding of commercially available dosages; expected renewed growth in Q3-Q4 as focus shifts to personalized semaglutide and oral offerings
- Canadian market opportunity: Generic semaglutide expected at $75-100 price point (versus $300-400 branded); represents structural access unlock in market where 2/3 of adults are overweight or obese
- International expansion rationale: Multi-year focused approach targeting handful of key markets rather than spray-and-pray model; ZAVA acquisition provides platform expertise in diverse regulatory environments
- AI strategy: Tactical near-term improvements through agent-centric model for providers, patients, and pharmacists; expect visible results within 3-6 months with use cases deployed across platform
Risks
- GLP-1 revenue headwinds from regulatory transition (503B to 503A facilities) causing shorter shipment cadence and lower revenue per order, with temporary Q3-Q4 impacts from in-quarter revenue recognition dynamics
- Sexual health on-demand business experiencing deliberate decline as company rotates to higher-margin daily offerings; recovery expected only in late 2026 as headwinds dissipate
- Tariff and supply chain uncertainty acknowledged; company proactively increased inventory in Q2 to hedge against potential disruptions, though management states no meaningful tariff pressure currently embedded in outlook
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.Company data
Company intelligence
Updated: Nov 13, 2026, 12:44 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Chief executive
- Andrew Dudum
- Employees
- 2,442
- IPO date
- Sep 13, 2019
- Country
- US
- Exchange
- New York Stock Exchange
Altman Z-scorei1.54
Piotroski scorei2/9
Overall ratingiC
Owner earningsi-$33.23M-$0.14 per share
ESG risk ratingiBIndustry rank: 12/78
Rating factors
- Return on equityi
- 1/5
- Return on assetsi
- 1/5
- Debt to equityi
- 1/5
- Price to earningsi
- 1/5
- Price to booki
- 1/5
Company press releases
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP AnnouncesBusiness WireHims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 DeadlinePRNewsWireKaplan Fox Notifies Investors of Hims & Hers Health, Inc. (HIMS) of the Lead Plaintiff Deadline on November 2, 2026Newsfile CorpHims & Hers Health, Inc. (HIMS) Investors: November 2, 2026, Deadline in Securities Fraud Class Action LawsuitPRNewsWireHIMS Investors with Losses in Excess of $100K Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud LawsuitPRNewsWireHims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMSGlobeNewsWire
Congressional disclosures
Market cap history
$4.61B-30.8%Aug 2026 – Nov 2026
Latest: $4.61B · 2026-11-12High: $7.20B · 2026-08-24Low: $4.61B · 2026-11-12
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| IJH | 0.17% | 7.4M |
| XAW.TO | 0.01% | 7.4M |
| NJH | 0.17% | 7M |
| VTI | 0.01% | 6.7M |
| IWM | 0.2% | 5.7M |
| VB | 0.08% | 4.9M |
| NJM | 0.17% | 4.8M |
| FSSNX | 0.23% | 2.9M |
| VBK | 0.18% | 2.8M |
| VXF | 0.07% | 2.5M |
| IWO | 0.4% | 2M |
| NLO | 0.32% | 1.7M |
Analyst track record
How the analysts covering HIMS have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 135 | 378 |
| Analysts | 19 | 26 |
| Buy / hold / sell | 29 / 90 / 16 | 94 / 216 / 68 |
| Upgrades / downgrades / initiations | 5 / 1 / 4 | 6 / 9 / 12 |
| Price targets hit / missed | 7 / 105 (6%) | 48 / 285 (14%) |
| Avg. return after a rating (TipRanks) | -29.3% | -24.5% |
| Best / worst call | +57.8% / -67.1% | +181.9% / -76.8% |
After buy calls on this stock: median 21-day move +4.2% vs S&P 500 +0.9% (n = 96)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Daniel GrosslightCiti95% hit rate on this stock · 22 targets measuredHoldtarget $33.00Aug 12, 2026
- Allen LutzBank of America Securities87% hit rate on this stock · 46 targets measuredHoldno targetNov 10, 2026
- Maria RippsCanaccord Genuity54% hit rate on this stock · 13 targets measuredBuytarget $40.00Nov 10, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 11, 2026 | Justin PattersonKeyBancNov 11, 2026 | HoldMaintained | –↗ | article ↗ |
| Nov 10, 2026 | Allen LutzBank of America SecuritiesNov 10, 2026 | HoldMaintained | –↗ | article ↗ |
| Nov 10, 2026 | Michael ChernyLeerink PartnersNov 10, 2026 | HoldMaintained | $24.00↗ | article ↗ |
| Nov 10, 2026 | Bryan SmilekJ.P. MorganNov 10, 2026 | HoldMaintained | $24.00↗ | article ↗ |
| Nov 10, 2026 | Mark MahaneyEvercore ISINov 10, 2026 | HoldMaintained | $27.00↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 13, 2026 · 135 ratings
Frequently asked questions
Where can I trade HIMS perpetual futures?
Hims & Hers Health, Inc. (HIMS) perpetual futures trade on 19 crypto venues, including Deepcoin, Binance, LBank. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade HIMS around the clock?
Yes. Unlike the underlying stock, HIMS perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on HIMS perpetuals?
Right now the HIMS perp funding rate is +5.5% annualized (venue median), ranging from +5.5% to +5.5% across 19 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the HIMS perp price compare to the Hims & Hers Health, Inc. stock?
The venue-median HIMS perp mark is $19.4 versus a reference stock price of $19.4, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a HIMS perpetual future?
A HIMS perpetual is a derivative that tracks the price of Hims & Hers Health, Inc. with no expiry date. It lets you take long or short exposure to Hims & Hers Health, Inc. on crypto venues, around the clock.
What is HIMSUSDT perpetual?
HIMSUSDT is the symbol most crypto exchanges use for the Hims & Hers Health, Inc. perpetual settled in USDT (Tether). It tracks the HIMS share price through an index, trades 24/7 with leverage and never expires.
Embed this asset
<a href="https://perpequities.com/stocks/hims-perp"><img src="https://perpequities.com/badge/hims-perp.svg" width="240" height="64" alt="HIMS perpetuals · perpequities.com" loading="lazy"></a>